<DOC>
	<DOCNO>NCT00514540</DOCNO>
	<brief_summary>The goal clinical research study learn effective 2 different schedule chemotherapy drug ( Paraplatin [ carboplatin ] plus Taxotere [ docetaxel ] VePesid [ etoposide ] plus Platinol-AQ [ cisplatin ] ) treatment patient anaplastic prostate cancer . The safety therapy combination also study .</brief_summary>
	<brief_title>Carboplatin Plus Docetaxel ( Taxotere ) Anaplastic Prostate Cancer</brief_title>
	<detailed_description>Carboplatin design interfere growth cancer cell stop cell division . Docetaxel design stop growth cancer cell , may cause cell die . It believe weakly effective kill blood vessel cancer cell well . Etoposide drug show interfere growth cancer cell , may cause eventually die . Cisplatin atom center contain platinum . The platinum suppose poison cancer cell , may cause eventually die . If find eligible take part study , receive carboplatin plus docetaxel vein central line vein . You receive carboplatin 30 minute docetaxel 60 minute . You receive therapy combination Day 1 cycle therapy ( every 3-4 week ) , depend recovery bone marrow . These 3-4 week consider 1 cycle therapy . This therapy combination give outpatient basis . If experience side effect , dose docetaxel plus carboplatin may decrease . You give dexamethasone , vein arm , central line vein , mouth , therapy begin docetaxel plus carboplatin . Dexamethasone help decrease bone marrow inflammation . You also give colony stimulate factor ( doctor think need ) help maintain white blood cell count help decrease chance infection . Colony stimulate factor give subcutaneous injection ( skin ) , discretion treat physician , therapy . You 2-3 tablespoon blood drawn begin cycle therapy routine blood test blood test cancer marker . You ask medication currently take . At end first 2 cycle therapy , scan ( perform screen visit ) repeat evaluate disease . If disease respond well therapy , continue docetaxel plus carboplatin 2 cycle . In case , continue receive study combination doctor think receive benefit . You follow scan ( perform screen visit ) every 2 month unless cancer progress ( get bad ) begin new therapy treatment end study . If already take hormone therapy luteinizing hormone-releasing hormone ( LHRH ) agonist ( Lupron Zoladex ) , continue take medication . If take anti-androgen drug ( Casodex ) , stop taking . If cancer progress maximal response , disease respond 2 course therapy , able tolerate side effect docetaxel plus carboplatin , chemotherapy switch etoposide plus cisplatin . If case , etoposide plus cisplatin give vein arm central line vein . You receive therapy combination day ( etoposide 60 minute cisplatin 2 hour ) first 3 day cycle therapy , therapy repeat every 3 4 week . Therapy etoposide plus cisplatin continued long cancer respond well therapy experience intolerable side effect . If experience side effect , dose etoposide plus cisplatin may decrease . This treatment combination may give inpatient basis . You remove study disease get bad experience intolerable side effect . If come study complete therapy , disease get bad , experience intolerable side effect , end-of-study visit . During visit , blood drawn ( 3 tablespoon ) routine test . You complete physical exam , include measurement vital sign . You also complete medical history record asked medication currently take . You image scan evaluate disease ( similar screening ) do last 28 day . Once long study , research staff periodically check ( every 6 month ) . This update consist phone call , e-mail , review medical and/or record . No clinic visit additional diagnostic study require study . If contact phone , call would last minute . This investigational study . Carboplatin , docetaxel , etoposide , cisplatin commercially available approved FDA . Up 120 patient take part multicenter study . Up 90 enrol MD Anderson .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Patient must androgen independent Stage IV prostate cancer , anaplastic feature define least one following : ) Histologic evidence small cell ( pure/mixed ) , locally advanced metastatic ; b ) Any follow Dx : exclusive visceral mets , predominant lytic mets , bulky ( &gt; /= 5 cm ) lymphadenopathy , bulky ( &gt; /= 5 cm ) highgrade ( Gleason &gt; /= 8 ) tumor mass prostate/pelvis c ) Low PSA Dx + high volume bone mets . 2 . ( # 1 cont 'd ) ) Neuroendocrine marker histology ( + Chromogranin A and/or Synaptophysin ) serum ( abnl high serum Chromogranin A Bombesin ) Dx progression plus following : elevate serum LDH , malignant HyperCa+ , elevate serum CEA absence etiology . e ) Short interval ( &lt; 6 month ) androgenindependent progression follow initiation hormonal therapy without presence neuroendocrine marker . 3 . Patients small cell carcinoma histology require receive prior androgen deprivation therapy ( ADT ) . All patient must evidence disease progression ADT unsatisfactory response &gt; /= 1 month castration , define lack symptom control and/or serum tumor marker response &lt; 20 % ( confirm second value draw different day ) . 4 . Zubrod performance status &lt; /= 2 . 5 . Normal EKG , EKG suggestive cardiomyopathy , patient resting Left Ventricular Ejection Fraction ( LEVF ) &gt; /= 50 % within 4 month . 6 . Patient follow pretreatment laboratory data within 14 day registration : • Absolute neutrophil count ( ANC ) &gt; =1,500/mm^3 . ( unless due bone marrow infiltration tumor , case ANC &gt; /= 500/mm^3 allow ) . • Platelets &gt; =100,000/mm^3 ( unless due bone marrow infiltration tumor , case platelet &gt; /= 20,000/mm^3 allow ) 7 . ( # 7 cont 'd ) • Total bilirubin &lt; /= 2 mg/dl ; great , conjugate bilirubin &lt; = 1.0 mg/dL , • SGPT ( ALT ) and/or SGOT ( AST ) &lt; /= 4 x ULN . • Creatinine clearance &gt; /= 40 ( either measure calculate Cockcroft formula ) • Castrate level serum testosterone ( &lt; /= 50ng/mL ) small cell element histology . ( If small cell , testosterone &gt; 50ng/mL ) 8 . Patient give voluntary write informed consent performance studyrelated procedure part standard medical care . 1 . Immunotherapy chemotherapy within four week ( nitrosoureas within six week ) registration . 2 . 2 prior chemotherapy regimen ( ketoconazole , aminoglutethimide dutasteride count chemotherapy trial ) . 3 . Prior Platinum , Etoposide , Taxanebased therapy complete less 6 month registration . 4 . Samarium153 within four week registration , Strontium89 within 12 week registration . Patients receive 2 dos boneseeking radioisotope eligible . 5 . Patient recover serious toxic effect previous chemotherapy , radiation antibody therapy , previous major surgery . 6 . Patients symptomatic untreated brain metastasis central nervous system disease exclude . Patients untreated , asymptomatic brain metastasis ( require corticosteroid treatment control CNS symptom ) may eligible , discretion MDACC Principal Investigator . Patients treat brain metastasis eligible . 7 . Patient significant atherosclerotic disease , define : ) myocardial infarction within six month enrollment . Current uncontrolled/unstable angina pectoris electrocardiographic evidence acute ischemia b ) clinically significant ventricular arrhythmia c ) symptomatic congestive heart failure ( NYHA Class III ) 8 . Patient &gt; = Grade 2 peripheral neuropathy . 9 . Patient renal insufficiency CrCL &lt; 40ml/min noncorrectable etiology . 10 . Patient uncontrolled intercurrent illness ( e.g. , active infection ) . 11 . Patient another serious medical psychiatric illness could , investigator 's opinion , potentially interfere patient 's ability provide inform consent completion treatment accord protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Anaplastic Prostate Cancer</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Paraplatin</keyword>
</DOC>